Меню
Идёт набор NCT05382572

Pulmonary Fibrosis Foundation Community Registry

— Наблюдательное Pulmonary Fibrosis Interstitial Lung Disease Lung Fibrosis Idiopathic Pulmonary Fibrosis

Ориентир для пациента и семьи

Простыми словами

Автоматическая сводка по структурированным данным реестра. Она помогает сориентироваться, но не заменяет официальный протокол или оценку врача.

Что изучают
Это наблюдательное исследование: исследуемое лечение участникам по протоколу не назначают.
Кому может быть актуально
Состояния в реестре: Pulmonary Fibrosis, Interstitial Lung Disease, Lung Fibrosis, Idiopathic Pulmonary Fibrosis. Базовые параметры: от 18 лет · Все.
Что важно проверить
Возраст, диагноз и пол — только базовые ориентиры. Предыдущее лечение, анализы и другие обязательные условия указаны ниже в критериях участия.
Где проводится
США
Следующий шаг
Сохраните исследование, покажите его лечащему врачу и уточните актуальный статус у исследовательского центра. Расходы, документы и поездка →

Не всё понятно в терминах? Прочитайте наш гид для пациентов →

Обзор

Pulmonary fibrosis (PF) results from a diverse group of health conditions and affects the lives of patients (including those who are post lung transplant), caregivers and family members. The Pulmonary Fibrosis Foundation Community Registry will offer an online portal where participants can self-enroll and directly contribute information about their experience with PF to be compiled into a longitudinal data set for use by researchers.

Подробное описание

The PFF Community Registry is an observational, longitudinal cohort study. The Community Registry will enroll three different cohort groups:

1. Patients with PF, including those who are post lung transplant 2. Caregivers of patients with PF 3. Family members of patients with PF

This is an online registry open to individuals affected by PF in the US. It is not associated with a physical location or institution. Individuals may self-enroll online and contribute data to the Community Registry by answering a series of surveys at regular intervals.

Participants may also elect to be contacted about future research projects through the PFF Community Registry portal. However, this is not required to participate in the Community Registry itself.

Первичные конечные точки

  • Number of patients who have or had interstitial lung disease (ILD) enrolled in the PFF Community Registry [Срок оценки: 3 years]
  • Number of caregivers of patients who have or had ILD enrolled in the PFF Community Registry [Срок оценки: 3 years]
  • Number of family members of patients who have or had ILD enrolled in the PFF Community Registry [Срок оценки: 3 years]

Критерии участия

Критерии включения

In order to be eligible to participate in this study, an individual must meet all of the following criteria:

  • Provision of signed and dated informed consent form online
  • Male or female, aged 18 or older
  • Affected by PF as a member of at least one of the following cohorts:
  • An individual diagnosed with PF or ILD, including those who are post lung transplant, or
  • An individual who has cared (currently or in the past) for an individual with PF or ILD, and / or
  • A family member (defined as parent, full or half-sibling, or child) of an individual with PF or ILD.
  • Has internet access and a valid email address.

Критерии исключения

An individual who meets any of the following criteria will be excluded from participation in this study:

  • Primary residence or place of care is outside of the US.
  • Inability or unwillingness of a participant to provide informed consent or comply with study protocol.
  • Any condition or circumstance not listed above, which, in the opinion of the investigator, may pose additional risks from participation in the study, may interfere with the participant's ability to comply with study requirements or that may impact the quality or interpretation of the data obtained from the study.
  • Patients who were diagnosed with any of the below lung diseases. Similarly caregivers and family members associated with these diseases would be excluded.
  • Sarcoid
  • Lymphangioleiomyomatosis (LAM)
  • Pulmonary alveolar proteinosis (PAP)
  • Cystic fibrosis (CF)
  • Amyloidosis

Критерии приведены из реестра в оригинале (на английском). Окончательную оценку соответствия проводит исследовательский центр.

Здоровые добровольцы: Да

Дизайн исследования

Модель наблюдения
Когортное

Центры проведения

США · 1 центр
  • Pulmonary Fibrosis Foundation — Chicago

Идентификаторы

NCT: NCT05382572 · HUM00202724

Первоисточники (государственные реестры)

Открыть это исследование на ClinicalTrials.gov ↗